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The endocannabinoid system refers to a widespread signaling system and its alteration is
implicated in a growing number of human diseases. However, the potential role of endo-
cannabinoids in skeletal muscle disorders remains unknown. Here we report the role of the
endocannabinoid CB1 receptors in Duchenne’s muscular dystrophy. In murine and human
models, CB1 transcripts show the highest degree of expression at disease onset, and then
decline overtime. Similar changes are observed for PAX7, a key regulator of muscle stem
cells. Bioinformatics and biochemical analysis reveal that PAX7 binds and upregulates the
CB1 gene in dystrophic more than in healthy muscles. Rimonabant, an antagonist of CB1,
promotes human satellite cell differentiation in vitro, increases the number of regenerated
myoﬁbers, and prevents locomotor impairment in dystrophic mice. In conclusion, our study
uncovers a PAX7–CB1 cross talk potentially exacerbating DMD and highlights the role of CB1
receptors as target for potential therapies.
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Duchenne’s muscle dystrophy (DMD) represents the mostfrequent form of hereditary myopathy. It is caused bymutations in the X-linked gene encoding for the struc-
tural protein dystrophin, which plays a critical structural role by
being part of the dystrophin–glycoprotein complex that physi-
cally connects the cytoskeleton to the surrounding extracellular
matrix through the cell membrane. Loss of dystrophin function
caused by large intragenic deletions (65% of the cases), intragenic
duplications (6–10% of the cases), or point mutations associated
to other sequence variations (30–35% of the cases) leads to pro-
gressive and irreversible muscle wasting and weakness. Since the
dystrophin gene is located on the X chromosome, the disease
mostly affects young boys with a frequency of approximately
1:35001–5.
Recent studies demonstrated that dystrophin plays a key role
also in satellite cells, the muscle stem cells normally deputed to
regenerate injured muscle ﬁbers, where the lack of the functional
protein causes asymmetric cell division, altered morphogenesis,
and inefﬁcient differentiation6,7. Although in both human and
murine DMD skeletal muscles the number of satellite cells is
higher than healthy tissue, their regenerative capacity is inevitably
compromised along with disease progression7–10.
The endocannabinoid signaling system (ECS) is composed of a
group of endogenous molecules including: (a) two endogenous
lipid mediators, anandamide (AEA) and 2-arachidonoyl-glycerol
(2-AG); (b) enzymes controlling AEA and 2-AG biosynthesis and
degradation; and (c) two AEA and 2-AG responsive G protein-
coupled receptors known as cannabinoid receptor of type 1 (CB1)
and type 2 (CB2)11–13. In mammals, the function of the ECS is to
control a large variety of physiological processes at both central
and peripheral levels11,12,14. However, the potential role of the
ECS in skeletal muscle disorders remains unknown. Recently, we
have shown that the muscle levels of 2-AG are decreased during
both myotube formation in vitro from C2C12 myoblasts and
mouse muscle development in vivo. We also reported that in
murine and primary human myoblasts the stimulation of CB1 by
endogenous 2-AG or synthetic agonists such as arachidonoyl-2-
chloroethylamide (ACEA), promotes myoblast proliferation while
counteracting myoblast differentiation. Opposite effects were
observed with rimonabant (SR141716) or AM251, two CB1
antagonists/inverse agonists15.
The aim of the present study was to explore the regulation and
function of the endocannabinoid CB1 receptor in skeletal muscle,
as well as isolated myoblasts and satellite cells from dystrophic
mdx mice or human DMD patients. We demonstrate the exis-
tence of a functional interplay between CB1 and PAX7, a key
factor regulating muscle regeneration through satellite cell divi-
sion, and that antagonism of CB1 prevents the loss of muscle
activity in dystrophic mice.
Results
CB1 and PAX7 expression in dystrophic skeletal muscles. In
order to deﬁne the expression levels of CB1 in dystrophic mus-
cles, we dissected from both control and mdx mice, the animal
model more used to study DMD16–18, the quadriceps, diaphragm,
soleus, and gastrocnemius muscles. All these tissues were isolated
at three different time points: (1) before the onset of the disease
(3 weeks of age); (2) at the onset of the disease (5 weeks), and (3)
3 weeks after the onset19.
Our qPCR analysis revealed that in the gastrocnemius and
quadriceps (vastus intermedius), CB1 mRNA levels show a bell-
shaped proﬁle with the highest degree of expression at disease
onset and declining then over time (Fig. 1a, b, upper panel). In
control muscles, instead, the mRNA levels of CB1 were always
comparable to the levels observed at 3 weeks in mdx mice
(Fig. 1a, b, upper panel). Intriguingly, the transcript levels of
PAX7, the most known master gene regulating satellite cell
activation and self-renewal20,21, showed an expression proﬁle
very similar to CB1 (Fig. 1a, b, lower panel). A similar expression
proﬁle of CB1 and PAX7 was also found in the diaphragm and
soleus muscle (data not included). To gain a mechanistic
understanding relative to the upregulated expression of CB1
gene in DMD muscles, and to deﬁne the speciﬁc muscle cell
subpopulation responsible for these changes, we performed RNA-
sequencing (RNA-seq) experiments on ﬂuorescence-activated cell
sorting (FACS)-sorted satellite, macrophage and ﬁbroadipogenic
progenitor (FAP) cells freshly isolated from the hind limb
muscles of 8-week-old control and mdx mice. As shown in the
heat map in Fig. 1c, this approach revealed that CB1 is expressed
in satellite, FAP, and, much less, macrophage cells. The
expression of speciﬁc markers of these cell subtypes is also
shown (Fig. 1c). Most importantly, we demonstrated that the lack
of dystrophin was accompanied by a signiﬁcant increase in the
transcript levels of CB1, occurring exclusively in satellite cells but
not in FAP or macrophages (Fig. 1c). The graph bar (Fig. 1d)
shows the quantiﬁcation of the results. Instead, CB2 was only
weakly expressed in satellite or FAP cells, and abundantly present
in macrophages, where its expression was signiﬁcantly increased
in mdx mice (Supplementary Figure 1).
To clarify whether the increased expression of CB1 observed in
dystrophic muscles was due to increased mRNA expression per
cell or instead depended on the increased number of PAX7+ cells,
we isolated satellite cells from the gastrocnemius of control and
mdx mice during (5 weeks) and after (8 weeks) the onset of
pathology. Our results, in agreement with previous ﬁndings6–8,
indicate that the total number of satellite cells isolated from
skeletal muscles of mdx mice was signiﬁcantly higher than in
control mice at both time points (Supplementary Figure 2).
However, the fold-increase in satellite cell number appeared to
account for increased expression of CB1 and PAX7 only at week
8 (approximately twofold increase of cell number), and much less
at week 5 (~1.5-fold of cell number), when the latter and,
particularly, the former gene appeared to be expressed more-fold
(approximately ﬁvefold and twofold) than what could be
accounted for by the increase of satellite cells.
CB1 receptor expression proﬁle in human DMD muscles. Since
mdx mice exhibit etiological and symptom differences with
human DMD17,18,22, we evaluated the expression proﬁle of CB1
and PAX7 genes in leg muscle biopsy specimens from both
healthy and DMD human donors. As shown in Fig. 2a, both
genes were signiﬁcantly upregulated in the muscle of 3-year-old
boys affected by DMD, when compared to age-matched healthy
controls, and lower in 7-year-old compared to 3-year-old DMD
boys. Data from healthy 7-year-old patients are not available,
since all the collected samples are usually true positives at this age
due to the fact that boys affected by DMD usually exhibit the ﬁrst
symptoms around 3–5 years of age 23.
2-AG levels in dystrophic murine and human muscles. In both
whole muscles and myoblasts of DMD boys (Fig. 2b and Sup-
plementary Table 1) as well as in the muscles of mdx mice
(Fig. 2c, d), we found levels of 2-AG in the µM range sufﬁcient to
constitutively activate CB1 receptors. No statistically signiﬁcant
differences were observed in 2-AG levels of healthy and DMD
donors (Fig. 2b), while higher levels of 2-AG were found in the
muscles of 3-week-old mdx mice (Fig. 2c, d). However, 2-AG
levels in both mdx mouse quadriceps and gastrocnemius, and in
control gastrocnemius, ﬁrst decreased (from 3 to 5 weeks of age)
and then increased (from 5 to 8 weeks of age). Interestingly, 2-AG
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levels in the gastrocnemius were higher in mdx mice at 8 weeks
than 3 and 5 weeks, when the tissue contained also the highest
number of satellite cells (Supplementary Figure 2), in agreement
with the hypothesis that these cells are an important source of the
endocannabinoid. Satellite cells from control and mdx mouse
hind limb muscles expressed similar levels of mRNAs of enzymes
for 2-AG biosynthesis and hydrolytic inactivation (Fig. 2e),
conﬁrming that these cells contain the enzymatic apparatus to
produce and inactivate 2-AG.
PAX7 directly regulates the transcriptional activity of CB1
gene. In view of the very similar expression proﬁle of PAX7 and
CB1 in both human and murine skeletal muscles affected by
DMD, we explored the possibility of a direct regulation of CB1
gene transcription by PAX7. To prove this, we used bioinformatics
tools to search for putative consensus sequences for PAX7 within
the CB1 gene. The human CB1 gene (CNR1) produces six splice
variants. Transcript variants 1, 3, 4, 5, and 6 encode full-length
CB1, which is 472 amino acids in length encoded without inter-
ruption by a single region in exon 4. Exon 4, however, can be
differentially spliced to remove 102 nucleotides (nts). This splicing
occurs in transcript variant 2 that encodes the truncated CB1
isoform b. The third isoform, named CB1a (or CB1 short), differs
by 167 nts from the isoform b. Furthermore, two transcriptional
start sites (TSS) are present at the 5′ end of exon 4. Translation
from the former site produces CB1 and CB1b. Translation from
the latter site is thought to produce the amino-terminal variant
CB1a24. On the other hand, the mouse and rat CB1 genes are
located on chromosomes 4 and 5, respectively. A single coding
variant of CB1 has been identiﬁed in these two species25. We
identiﬁed distinct putative PAX7 binding sequences with a high
homology score (>90) in both human and murine CB1 encoding
genes. In human CB1 gene, we found two PAX7-rich sites located
at −560 and −427 bp from the TSS producing the isoforms CB1
and CB1b. Three rich regions were instead found at −427, −390,
and−338 from the TSS producing the isoform CB1a or CB1 short.
Additionally, a further PAX7-rich region was detected 1175 bp
downstream the TSS of CB1a (Fig. 3a). In murine CB1 gene, we
found two distinct putative consensus regions for PAX7 located in
the 5′UTR region at −232 and −182 bp of distance from TSS
(Fig. 3b). Chromatin immunoprecipitation (ChIP) analysis
showed that the transcription factor PAX7 effectively binds the
putative responsive sequences identiﬁed within the CB1 encoding
genes. Brieﬂy, in these experiments, the genomic DNA was iso-
lated from gastrocnemius muscles of both control and mdx mice
at 5–6 weeks of age and used for the immune-afﬁnity reaction with
a speciﬁc anti-PAX7 antibody. Subsequently, using speciﬁc pair of
primers able to amplify the genomic portion of interest of the CB1
gene containing the putative PAX7 binding sites (Fig. 3a, b, red
arrows), we found that PAX7 effectively binds these sites and that
the amounts of the complex are signiﬁcantly higher in muscles of
dystrophic than healthy mice (Fig. 3c, left). To prove the binding
of PAX7 to the human CB1 gene, we repeated the ChIP procedure
in primary human PAX7-silenced satellite cells. In these latter
experiments, due to the fact that ChIP analysis requires a
large number of cells, we were able to study the potential binding
of PAX7 to CB1 only within region 2. This portion of the
gene was preferred to the other two (regions 1 and 3) because it
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Fig. 1 CB1 and PAX7 gene expression in dystrophic skeletal muscles and cells. a, b Time course of CB1 and PAX7 mRNA expression levels in gastrocnemius
(a) and quadriceps (b) muscle of control (dark yellow columns) and mdx (red columns) mice of 3 (n= 8), 5 (n= 8), and 8 (n= 8) weeks of age. The
quantiﬁcation of transcripts for CB1 and PAX7 was performed by quantitative real-time PCR. c Heatmap representation of selected genes obtained from
RNA-seq analysis in ﬁbroadipogenic (FAP), satellite (SC), and macrophage (MP) cells isolated from 8-week-old control (n= 4) and mdx (n= 4) mice. Red,
upregulated; green, downregulated. d Bar graph showing RPKM (Reads Per Kilobase of transcript per Million mapped reads) normalized values for the CB1
gene obtained from RNA-seq analysis in isolated FAP, SC, and MP cells. Each bar is the mean ± SEM of the independent determinations. *P≤ 0.05 vs.
control animals or cells, determined by Student’s t test
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contains the highest number of putative PAX7 binding sites
(Fig. 3a). Furthermore, we transfected human satellite cells with
siRNA sequences against PAX7 and collected them after 48 h to
perform ChIP analysis. As shown in the right panel of Fig. 3c
(right), we found in PAX7-silenced primary satellite cells a ~50%
reduction of the intensity of the signal corresponding to the
binding of PAX7 to CB1.
To test the efﬁcacy of the siRNA sequences used to target
PAX7, we performed qPCR and western blot analyses, which
conﬁrmed not only the knockdown of the transcription factor but
also that of its major target LIX126, and of the CB1 (but not CB2)
gene (Supplementary Figure 3).
Finally, we utilized human embryonic kidney (HEK293) cells
to overcome the problems due to the difﬁculty of isolating a
sufﬁcient number of human satellite cells to perform functional
luciferase assays. When HEK293 cells were transiently transfected
with human PAX7 or control plasmid (scramble), our ChIP
analysis conﬁrmed that PAX7 binds with high afﬁnity the
endogenous CB1 gene within regions 2 and 3 (Fig. 3d). We then
conﬁrmed that PAX7 binding to CB1 enhances its transcription
by performing luciferase assays following the cloning of the
portion of either the human or murine CB1 gene containing
the PAX7 consensus regions in a PGL3 plasmid, upstream of the
luciferase gene. In particular, we cloned: a) two human CB1
genomic portions of interest including the two distinct PAX7
consensus regions identiﬁed at 5′UTR and downstream the TSS
region of CB1a (370 and 319 bp, black bars Fig. 3a, b) the murine
CB1 portion of interest, including the two sites identiﬁed in the 5′
UTR region (703 bp, black bar Fig. 3b). The three constructs were
separately transfected into HEK293 cells with or without a
plasmid expressing PAX7, which expressed the protein at
detectable levels in a variety of non-muscle cell lines. As shown
in Fig. 4, when HEK293 cells were transfected with the plasmid
carrying the murine or human CB1 genomic portion of interest in
the presence of PAX7, the chemiluminescent signal intensity was
signiﬁcantly higher (by about threefold and 6.5-fold, respectively)
than when PAX7 was not co-expressed.
Taken together, these results indicate that the transcriptional
factor PAX7 directly regulates CB1 gene expression by promoting
its transcriptional activity in both murine and human species,
showing more efﬁcacy during DMD progression.
Pharmacological role of CB1 in human muscle cells. Using
western blot analysis, we found that the CB1 protein is expressed
in PAX7-positive primary human satellite cells (Fig. 5a). Then,
when these cells were induced to differentiate into myotubes, we
found that blockade of CB1 receptor by rimonabant (1–3 µM)
increased the expression of troponin-T-1 (TNNT1), myogenin
(MYOG), and myosin heavy chain (MyHC), canonical markers of
myogenesis27 (Fig. 5b, c), while it reduced the proliferation rate of
satellite cells (Supplementary Figure 4). The stimulation of CB1
by 2-AG or ACEA (3 µM) produced the opposite effects (Sup-
plementary Figure 4).
To test a potential endocannabinoid-based therapeutic treat-
ment for DMD patients, and given the remarkable difﬁculty in
isolating satellite cells from a muscle biopsy specimens28, we
isolated primary myoblasts from nine different donors (ranging
from 1 to 7 years old) diagnosed with DMD caused by different
mutations in the dystrophin gene (Supplementary Table 2).
Proliferating myoblasts at a conﬂuency of about 80–90% were
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Fig. 2 CB1 and PAX7 expression and 2-AG levels in dystrophic muscles. a mRNA expression levels of CB1 and PAX7 in muscle samples of healthy children
(HT, controls n= 3) or DMD donors of 3 (n= 4) and 7 (n= 4) years. b Measurement of the endogenous levels of 2-AG in muscle samples of the same
healthy and DMD donors. Time course of the endogenous levels of 2-AG in the quadriceps (c) and gastrocnemius (d) muscle of control (dark yellow; n=
8) and mdx (red columns; n= 8) mice. The levels of 2-AG are expressed as pmol mg−1 of wet tissue weight. *P≤ 0.05 vs. control group, determined by
Student’s t test. e The bar graphs show RPKM (Reads Per Kilobase of transcript per Million mapped reads) normalized values for the Daglα and Magl genes
obtained from RNA-seq analysis in satellite cells isolated from 8-week-old wt (n= 4) and mdx mice (n= 4)
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exposed to the differentiation media plus vehicle (dimethyl
sulfoxide (DMSO)) or rimonabant (1 µM) for 5 days. At the end
of treatment, the expression of MYOG and TNNT-1 was
quantiﬁed by qPCR analysis. We found that rimonabant
increased the expression of TNNT-1 and MYOG in differentiat-
ing myoblasts isolated from patients D1 to D6, whereas in
patients D7-D8 and in patient D9 there was a partial or no effect,
respectively (Fig. 5d). However, when combining the results of
myoblasts from all patients, we observed a signiﬁcant difference
in the expression levels of MYOG and TNNT-1 between vehicle
(DMSO) and rimonabant-treated myoblasts (Fig. 5e).
Effect of CB1 antagonism on locomotor activity in mdx mice.
We next treated mdx mice with ACEA or rimonabant and
measured their muscle coordination and strength by the use of
rotarod and weight holding tests. These are currently the most
commonly used tests to evaluate muscle skills in dystrophic
mice29,30. At the week of disease onset (5 weeks), dystrophic mice
were randomized into three groups, receiving vehicle (DMSO,
control), 0.5 mg Kg−1 rimonabant, or 2.5 mg Kg−1 ACEA. Each
drug was injected intraperitoneally three times per week. As
shown in Fig. 6a, at 5 weeks, the locomotor activity of mdx mice,
when compared to control animals, was signiﬁcantly reduced, and
then further worsened at 7 weeks (Fig. 6a). At 7 weeks, mdx mice
treated with rimonabant, but not ACEA, for 2 weeks showed a
signiﬁcant recovery of their muscle coordination (Fig. 6a). In
order to gain information about the effect of rimonabant in a
more advanced stage of disease, we repeated the rotarod test at 12
and 18 weeks in the same group of mice chronically treated with
rimonabant every other day commencing from week 5 (Fig. 6a,
the treatment is indicated as chronic). In addition, we also looked
at control and mdx mice at an even later stage following rimo-
nabant treatment given every other day starting from week 16
until week 18 (Fig. 6a, the treatment is indicated as 18 short). In
either case, rimonabant still prevented the loss of motor coordi-
nation. In the weight test, mdx mice were held by the middle/base
of their tail to allow them to grasp the weight (from 20 to 60 g).
From the moment the mouse grasps the weight with its forepaws,
the interval of time during which the mouse can hold the weight
is recorded and a score is assigned30. Also in this case, we found
that, as compared to control, in mdx mice muscle strength was
signiﬁcantly impaired at 5 weeks of age, and that, at 7 weeks,
rimonabant, but not ACEA, signiﬁcantly rescued the loss of
strength (Fig. 6b). The rescue was also observed at 12 and
18 weeks following both treatment regimens with rimonabant
(Fig. 6b). Finally, the above therapeutic effects of rimonabant
were conﬁrmed also with a 2-week late treatment in aged mice,
from 32 to 34 weeks (Fig. 6a, b).
Effect of CB1 antagonism on muscle regeneration in mdx mice.
We next isolated skeletal muscles from mdx mice at the end of
treatment to perform histological analyses following sectioning
and staining with hematoxylin and eosin (H&E), which is com-
monly used to evaluate changes in the number of healthy or
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necrotic myoﬁbers, position of nuclei within each myoﬁber, tissue
inﬁltration of inﬂammatory or fat cells, ﬁbrosis, etc31. The H&E
staining revealed that in the gastrocnemius of 7-week-old dys-
trophic mice, there was a signiﬁcant degeneration of skeletal
muscle structures as compared to control animals of the same
age, as shown in representative images (Fig. 7a). This was char-
acterized by a robust reduction in the number of myoﬁbers or of
their diameter with centrally positioned nuclei (Fig. 7a). Treat-
ment with rimonabant prevented these features (Fig. 7a) and
signiﬁcantly increased the number of regenerated myoﬁbers,
which exhibited larger size than both wild type and control group
(Fig. 7a). All the effects observed in rimonabant-treated mdx mice
were quantiﬁed and reported in the graphs (Fig. 7b–e). Somehow
less strong, but still signiﬁcant, protective effects were found in
the quadriceps (vastus intermedius) (Supplementary Figure 5).
This different efﬁcacy might be due to the higher proportion of
slow twitch ﬁbers in vastus intermedius than in gastrocnemius,
where CB1 is more abundantly expressed32,33 (Supplementary
Figure 5). This could suggest that tonic activation of CB1 in the
quadriceps is lower than in the gastrocnemius, also by virtue of
the lower levels of 2-AG between 5 and 8 weeks of age (Fig. 2),
and hence less efﬁcaciously unmasked by a saturating dose of
rimonabant. In addition, we isolated satellite cells from the gas-
trocnemius of control and dystrophic mice treated with rimo-
nabant or vehicle. We found that, in mdx mice, rimonabant
signiﬁcantly reduced the number of satellite cells as compared to
vehicle-treated mice and, at week 5, also to healthy mouse gas-
trocnemius (Fig. 7e), in agreement with the pro-differentiating
effect of the CB1 antagonist observed here also in vivo (see
below).
In summary, we show that in vivo, more prominently than
in vitro, CB1 antagonism reduces the amount of proliferating
satellite cells. In addition, the fact that after treatment with
rimonabant the number of proliferating satellite cells was lower
than in control mouse muscles, likely indicates that in dystrophic
muscles PAX7 positively regulates CB1 to promote its tonic
activation by endocannabinoids, which in turn increases the
proliferative status of satellite cells.
Rimonabant reduces the expression of degenerative markers.
We evaluated the transcript levels of known genes involved in the
inﬂammatory and degenerative process in the muscles of control
and mdx mice of 7 weeks treated with rimonabant or vehicle. In
the gastrocnemius and quadriceps of dystrophic mice, compared
to control littermates, we found a signiﬁcant decrease in the
expression level of MyHC and neoMyHC (Fig. 8a, c, e), and,
conversely, an increase of the inﬂammatory markers, interleukin
6 receptor (IL6R), tumor necrosis factor-α (TNFα), transforming
growth factor β (TGF-β), and inducible nitric oxide synthase
(iNOS) (Fig. 8a, d, f). In these muscles, 2-week treatment with
rimonabant caused a partial or full recovery in the expression
levels of neoMyHC and MyHC (Fig. 8a, c, e), whilst reducing the
transcript levels of IL6R, TNFα, TGF-β, and iNOS (Fig. 8b, d, f).
We also measured by ELISA the plasma levels of IL6 and TNFα in
control and mdx mice treated with rimonabant from 5 to
18 weeks of age every other day. As expected, plasma levels of
both IL6 and TNFα were considerably increased in mdx mice,
and rimonabant fully reversed this effect (Fig. 8e, f).
Intracellular mechanism coupled to CB1 receptor stimulation.
In our previous study, we demonstrated that the stimulation of
CB1 activates a typical G protein-coupled receptor-mediated
signaling mechanism, that is, the hydrolysis of 4,5-bisphosphate
(PIP2), thereby causing the inhibition of myogenesis-promoting
voltage-gated potassium Kv7.4 channels12. The formation of
diacylglycerols (DAGs) and inositol trisphosphate (IP3) is known
to occur as consequence of protein Gq-mediated PIP2 hydrolysis.
Therefore, in order to characterize also in satellite cells the
CB1 signaling cascade, we measured the levels of DAGs following
CB1 stimulation with ACEA. We found that exposure of satellite
cells to ACEA (3 µM) for 20 min elevated the intracellular levels
of two arachidonic acid-containing DAG species. Since these
DAGs may also act as biosynthetic precursors of 2-AG34, we also
measured the levels of this endocannabinoid, and found them to
be signiﬁcantly increased (Fig. 9a, b). These results raise the
possibility that CB1 stimulation may generate a positive loop
through increased production and signaling of 2-AG.
In addition, being the members of protein kinase C subfamily
(PKCs) preferential targets of DAGs in different cell types35,36, we
hypothesized their potential involvement as downstream targets
of CB1 receptors. It is known that PKC activation occurs through
phosphorylation at distinct sites including Thr-494, Thr-495, and
Thr-49736. Therefore, by means of western blot analysis
performed using a selective phospho-speciﬁc antibody directed
against the Thr497 site (common to all PKC isoforms), we
analyzed potential changes in PKC phosphorylation in human
satellite cells following CB1 stimulation. We found that, in
agreement with its stimulation of DAG production, ACEA also
increased phosphorylation of PKCs at Thr497, without affecting
their expression (Fig. 8c). Notably, in the gastrocnemius of mdx
mice at 8 weeks, we found a signiﬁcant increase in PKC
phosphorylation, which might depend on the tonic activation of
CB1 by 2-AG, when the levels of this endocannabinoid are
highest (Fig. 8d). It is worth noting that PKCs are known to: (a)
directly inhibit voltage gated Kv7 K+ channel activity37 and (b)
exacerbate the inﬂammatory and immune response in DMD38,39.
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These results further support the potential use of CB1
antagonists, rather than agonists, to treat DMD.
Discussion
Although great advances have been made toward a long-term
therapeutic approach to treat DMD, there is still no cure. Com-
plementary and/or supportive therapies are currently used to
delay and/or reduce the severity of symptoms2. Our previous
ﬁnding of the crucial role of the endocannabinoid 2-AG and its
receptor, CB1, in controlling myoblast proliferation and differ-
entiation in vitro and during early muscle development12 raised
two important questions: (1) is the endocannabinoid system
important also for the very ﬁrst step in muscle formation, i.e., the
generation of myoblasts from satellite cells? (2) Can pharmaco-
logical manipulation of CB1 receptors be useful to help treating
the symptoms, or delaying the progress, of muscular dystrophies
such as DMD? The former question is also relevant to the latter
one, since satellite cell dysfunction represents a major feature in
muscles affected by DMD. In fact, it was reported that the
number of these cells is higher in DMD muscles6–9 (a ﬁnding
conﬁrmed in the present study), although their ability to form
mature myotubes is compromised, this being one of the main
causes of the defective skeletal muscle repair observed in dys-
trophic muscles40,41; whereas satellite cell number remains
unchanged in less severe forms of muscular dystrophy42. Evi-
dence indicates that satellite cell functionality is also indirectly
affected by the hostile, e.g., pro-inﬂammatory and pro-ﬁbrotic,
microenvironment of the dystrophic muscle40,43, which antag-
onism of CB1 should also ameliorate44.
Here we showed that: (1) CB1 is overexpressed in the skeletal
muscle and satellite cells of mdx mice, as well as in muscle
biopsies of DMD patients, when the ﬁrst signs of the disease
occur, and concomitantly with a peak in expression of PAX7, a
key transcription factor and biomarker for satellite cells; (2) CB1
upregulation in satellite cells of mdx mice cannot be accounted
for uniquely by the increased number of these cells in dystrophic
muscles, especially at the onset of disease, and hence must be the
result of the overactivation of some regulatory pathway; (3)
accordingly, PAX7 upregulates the expression of both human and
mouse recombinant CB1 in host cells, and binds to the Cnr1 gene
in wild type and, to a higher extent, mdx mouse muscle, using
speciﬁc consensus sequences on this gene; (4) antagonism of CB1
receptors, opposite to their activation, reduces human satellite cell
proliferation; in addition, it enhances the formation of myotubes
from either satellite cells from healthy tissue, or human myoblasts
from DMD patients; and (5) CB1 antagonism in mdx mice,
starting at an early age, when their skeletal muscle exhibit the
highest expression levels of CB1 and sufﬁcient amounts of 2-AG
to activate them, might represent a tool to counteract the loss of
muscle strength in dystrophic mice, by enhancing muscle tissue
regeneration and possibly reducing inﬂammation and ﬁbrosis.
In the muscle tissues of young boys with DMD, we found low
micromolar concentrations of 2-AG and high CB1 expression.
This observation led us to hypothesize that increased endo-
cannabinoid tone in dystrophic muscles could somehow
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participate in the reduced ability of muscle precursor cells to
terminate their differentiation into mature myotubes. This
hypothesis was conﬁrmed by our ﬁndings in: (1) primary human
satellite and/or myoblast cells isolated from healthy and DMD
patients, where antagonism of CB1 receptor promoted differ-
entiation; and (2) mdx mice, where rimonabant increased sig-
niﬁcantly the number of healthy/regenerating ﬁbers, and
decreased inﬂammatory markers. It is not possible to assess
whether the effect of rimonabant on satellite cell differentiation
was due to reduced proliferation or vice versa. Since CB1 acti-
vation by ACEA signiﬁcantly enhanced proliferation but
appeared to reduce differentiation to a smaller extent, it is pos-
sible that the two processes are not solely the consequence of the
other, and, in this case, CB1 antagonists would have the advan-
tage of independently ameliorating two signs of DMD, i.e.,
satellite cell excessive proliferation and impaired differentiation.
Likewise, from our biochemical and histological analyses of mdx
mice at the end of treatment, it is not possible to conclude
whether the effect of rimonabant in vivo on muscle regeneration
is the product of reduced inﬂammation or if the latter effect is a
consequence of improved muscle regeneration. Appropriate stu-
dies, with time-course analyses of the various effects of rimona-
bant, need to be performed in order to answer this question, and
might demonstrate two independent effects of CB1 antagonism,
as suggested by our present data in human DMD myoblasts and
previous evidence of the anti-inﬂammatory properties of rimo-
nabant45,46. Interestingly, the antagonist did not enhance to the
same extent differentiation of myoblasts from DMD patients with
different mutations of the dystrophin gene. There is clinical evi-
dence demonstrating that the type of mutated dystrophin does
not necessarily correlate with the severity of the disease47,48.
Often, in patients with the same mutation disease severity can
vary, sometimes even within the same family49,50. Therefore, it is
difﬁcult to correlate the different pro-differentiating effects of
rimonabant in myoblasts isolated from different patients with the
potential clinical or genetic characteristics of the latter. A differ-
ent pharmacogenomic proﬁle among DMD patients could be one
of the main factors determining the response to rimonabant.
Future studies on a larger sample of patients are required to fully
investigate this hypothesis.
Overactivity of the endocannabinoid system has been described
in a large number of disorders including chronic inﬂammatory
conditions involving both central and peripheral systems51. For
example, in some metabolic dysfunctions caused by excessive
inﬂammation and oxidative stress and characterized by elevated
endocannabinoid tone and CB1 expression (i.e., obesity, high fat
diet and alcohol-induced liver steatosis/ﬁbrosis, high fat diet-
induced β-cell dysfunction, doxorubicin-induced cardiomyo-
pathy, high cholesterol-induced atherogenesis, etc.), CB1 inacti-
vation reduces the inﬁltration of immune cells, ﬁbrosis, and ROS
production in several peripheral organs52. Thus, CB1 antagonism
as an add-on therapy in DMD might also result in the sparing of
steroidal anti-inﬂammatory drugs, which are responsible for
serious side effects in children affected by this disease53. Addi-
tionally, recent studies (and our unpublished data) on the nega-
tive effects of CB1 activation on acetylcholine release from the
neuromuscular junction54–56 suggest that CB1 antagonists may
also effectively ameliorate muscle contraction. However, pre-
liminary data from our laboratory on the lack of rimonabant
effect on the isometric contraction of gastrocnemius muscles
from 8 weeks old mdx mice, evoked by selective stimulation of
the nerve in vivo, suggest that the beneﬁcial effects of CB1
antagonism in the rotarod and weight test, reported here, may not
be due to direct amelioration of muscle contraction performance.
In conclusion, we uncovered a potential vicious circle caused
by excessive satellite cell proliferation and PAX7 overexpression,
subsequent PAX7 binding to CB1, overexpression of this gene
and CB1 overactivity, with further satellite cell proliferation and
reduction of differentiation. We propose that the endocannabi-
noid system participates in the development of degenerative
muscle disease, through effects on muscle differentiation, regen-
eration, and repair processes, and suggest that CB1 receptor may
represent a potential target for the adjuvant therapy of muscle
dystrophies.
Methods
Cell culture, reagents, and transfections. Primary human satellite cells were
provided by Innoprot (Cat. no. P10976; Bizkaia-Spain) or Sciencell (Cat. no. 3510;
Carlsbad, CA, USA). Satellite cells were propagated in a growth medium (GM)
recommended by Innoprot (Skeletal Muscle Cell Medium, cat. no. P60124).
Myotube differentiation was achieved after exposure of satellite cells to a skeletal
muscle cell differentiation medium (DM) provided by Applied Stem Cell (Cat. no.
ASE-5064; CA, USA).
Primary myoblasts were established from the muscle biopsy of DMD affected
donors after they had signed informed consent forms and in accordance with the
guidelines of the G. Gaslini Institute Ethical Committee. The myoblasts were grown
in Full Aneural Medium [Dulbecco’s Modiﬁed Eagle Medium (DMEM) High
glucose supplemented with 15% FBS, 20% Medium 199, 1% insulin, 1% glutamine,
and 1% penicillin and streptomycin, FGF, EGF]. All the reagents were provided by
Life Technologies (Milan, IT).
HEK293 (Human Embryonic Kidney-293; ATCC Number: CRL-11268) cells
were propagated in Minimum Essential Media (MEM, cat. no. 31095-029
Invitrogen, Milan, IT) supplemented with 10% fetal bovine serum (FBS), 50 U/ml
penicillin plus 50 µg/ml streptomycin, and 1% L-glutamine (Invitrogen, Milan, IT),
in a humidiﬁed atmosphere of 95% air/5% CO2 at 37 °C.
For cell transfection, primary human satellite cells were plated in six multiwell
culture dishes; the day after plating, cells were transfected with the esiRNA
sequences targeting PAX7 (cat. no. EHU023151, Sigma-Aldrich, Milan, IT) using
Lipofectamine RNAiMAX (cat. no. 13778150, ThermoFisher Scientiﬁc, Milan, IT)
according to the manufacturer’s instructions.
HEK293 cells were seeded onto 24-well plastic plates at a 2 × 103 cells/cm2
density. After plating, the cells were transfected on the next day with: (a) pGL3
promoter vector (Promega, IT; cat. no. E176A) with the portion of interest human
or mouse CB1 gene cloned upstream the luciferase gene; (b) human PAX7 GFP-
tagged plasmid (Origene, MD USA; cat. no. RG216836); (c) pCDNA3 (Life
Technology, Milan, IT, cat. no. V79020); (d) a plasmid encoding for pSV-β-
Galactosidase control vector (Promega, IT; cat. no. E1081) was used to normalize
the signals and as positive control vector for monitoring transfection efﬁciency.
The combination of plasmids was transfected into the cells by use of Lipofectamine
LTX (Life Technology, MI IT) following the manufacture’s instruction.
The isolation of satellite cells from mouse skeletal muscle was performed using
the gentleMACSTM Dissociator (cat. no. 130-093-235) following the protocol of the
skeletal muscle dissociation kit (cat. no. 130-098-305) and the satellite cell isolation
kit, mouse (cat. no. 130-104-268). After isolation, cells were counted using an
automatic cell counter (Scepter 2.0, Merk Millipore).
Luciferase assay. After 48 h, the cells were harvested to detect the luciferase gene
reporter activity by the use of the luciferase assay kit (cat. no. LUC1, Sigma-Aldrich
MI, IT); whereas the β-galactosidase activity was detected with the β-galactosidase
detection kit (cat. no. Gal-A, Sigma-Aldrich, Milan, IT). The signal intensity of β-
Gal was measured at a microplate readers station (Tecan Geniuspro). Whereas, the
signal intensity of ﬁreﬂy luciferase was detected on a ChemiDoc MP System station
and reported as normalized with respect to the β-Gal.
Bioinformatics and ChIP analysis. Putative PAX7 consensus sequences identiﬁ-
cation were identiﬁed using the match tool of Transfac. The ChIP assay was
performed by the use of ChIP Kit (Sigma-Aldrich, Milan, IT; cat. no. CHP1)
following the manufacturer’s instructions. The genomic DNA was sonicated,
immunoprecipitated overnight at 4 °C with an antibody directed against PAX7
validated for ChIP (anti-PAX7 used at 2 µg/ml; Millipore, clone 2F12H4).
Immunoprecipitated DNA was then analyzed by qPCR (40–45 cycles) using pri-
mers amplifying each of PAX7-rich regions identiﬁed (Supplemental Table 3). In
addition, for each primer pair, non-immunoprecipitated DNA was used as input
for normalization. All ChIP assays were performed in triplicate for at least three
different biological preparations.
Western blot and immunocytochemistry analysis. Satellite cells were washed
two times in cold PBS (without Ca2+ and Mg2+, pH7.4) and lysed with lysis
solution (150 mM NaCl, 1 mM EDTA, pH 7.4, 10 mM Tris-HCl, pH 8, 1% SDS,
and 1% protease inhibitors). The same lysis solution was used to extract the protein
from whole skeletal muscle tissues. Each animal was previously anesthetized, and
once decapitated, the skeletal muscles were quickly dissected and washed twice in
cold PBS. After the homogenization cell and/or tissue lysates were kept in orbital
ARTICLE NATURE COMMUNICATIONS | DOI: 10.1038/s41467-018-06267-1
10 NATURE COMMUNICATIONS |  (2018) 9:3950 | DOI: 10.1038/s41467-018-06267-1 | www.nature.com/naturecommunications
shaker incubator at 6 g 4 °C for 30 min and then centrifuged for 15 min at 13,000×g
at 4 °C. The supernatants was transferred to clear tubes and quantiﬁed by DC
Protein Assay (Bio-Rad, Milan, IT). Subsequently, the samples (70–80 μg of total
protein) were boiled for 5 min in Laemmli SDS loading buffer and loaded on
8–10% SDS-polyacrylamide gel electrophoresis and then transferred to a PVDF
membrane. Filters were incubated overnight at 4 °C with the following primary
antibodies: (a) mouse anti-CB1 (1:500; cat. no. Y080037, Applied Biological
Materials Inc.); mouse anti-PAX7 (1:500; SantaCruz CA USA, cat. no. sc-81648);
rabbit anti PKC-pan (phospho Thr497; 1:500; Thermo Fisher Scientiﬁc; cat.
no. GTX52316); rabbit anti PKC-pan total (1:500; Thermo Fisher Scientiﬁc; cat.
no. GTX52352). An anti-α-tubulin antibody (1:5000; Sigma-Aldrich) was used to
check for equal protein loading. Reactive bands were detected by chemilumines-
cence (ECL-plus; Bio-Rad). Reactive bands were detected by chemiluminescence
(ECL-plus; Bio-Rad, Segrate, IT). The intensity of bands was analyzed on a Che-
miDoc station with Quantity-one software (Bio-Rad, Milan, IT). Uncropped
immunoblot image data. See Supplementary Figure 6 for uncropped images of key
immunoblot data presented in this study. In immunocytochemistry analysis, pri-
mary human satellite cells were plated in growth media (GM) on glass coverslips
treated overnight with poly-L-lysine (2 mg cm−2). The next day, GM was replaced
with the differentiation media (DM) containing vehicle (DMSO) or rimonabant (1
µM). After 5 days of exposure to DM with/without rimonabant, the cells were
harvested for qPCR analysis.
Measurements of endocannabinoids and DAGs. Frozen muscle tissue samples
were homogenized in chloroform/methanol/TRIS-HCl 50 mM, pH 7.4 (2:1:1, v/v),
containing 5 pmol of [2H]8-AEA, 50 pmol of [2H]5-2-AG, [2H]4-PEA, and [2H]2-
OEA as internal deuterated standards (purchased from Cayman Chemicals, Ann
Arbor, MI, IT). The extract was puriﬁed by means of silica gel mini-columns, and
the eluted fraction containing endocannabinoids and endocannabinoid-like
molecules analyzed by means of liquid chromatography–atmospheric pressure
chemical ionization–mass spectrometry (LC-APCI-MS). LC analysis was per-
formed in the isocratic mode using a Discovery C18 column (15 cm × 4.6 mm,
5 µm) and methanol/water/acetic acid (85:15:0.1 by vol.) as mobile phase with a
ﬂow rate of 1 ml min−1. Analyses were carried out in the selected ion-monitoring
mode using m/z values of 356 and 348 (molecular ions+ 1 for deuterated and
undeuterated AEA), 384.35, and 379.35 (molecular ions+ 1 for deuterated and
undeuterated 2-AG). AEA and 2-AG levels were therefore calculated on the basis of
their area ratios with the internal deuterated standard signal areas. Lipid amounts
expressed as pmol were then normalized per gram or milligram of wet tissue. To
measure DAGs, satellite cells were dounce-homogenized and extracted with
chloroform/methanol/Tris–HCl 50 mmol l−1 pH 7.5 (2:1:1, vol/vol) containing
internal standard, the 1,2-heptadecanoin (Larodan AB, Malmo, Sweden). The lipid-
containing organic phase was dried down, weighed, and pre-puriﬁed by open-bed
chromatography on silica gel. Fractions were obtained by eluting the column with
99:1, 90:10, and 50:50 (v/v) chloroform/methanol. The 90:10 fraction was used for
AEA and 2-AG quantiﬁcation by LC-APCI-MS by using a Shimadzu high-
performance liquid chromatography apparatus (LC-10ADVP) coupled to a Shi-
madzu (LCMS-2020) quadrupole mass spectrometry via a Shimadzu atmospheric
pressure chemical ionization interface. LC analysis was performed in the isocratic
mode using a Discovery C18 column (15 cm × 4.6 mm, 5 µm) and methanol/water/
acetic acid (85:15:1 by vol.) as mobile phase with a ﬂow rate of 1 ml min−1. The
amounts of endocannabinoids in plasma, quantiﬁed by isotope dilution with the
above mentioned deuterated standards, are expressed as pmol ml−1 of plasma
volume or milligram of lipid extract weight. The 99:1 fraction was used for DAGs
quantiﬁcation by iquid chromatography-tandem mass spectrometry (LC-MS-MS)
using an LC20AB coupled to a hybrid detector IT-TOF (Shimadzu Corporation,
Kyoto, Japan) equipped with an ESI interface. DAGs were separated using a Dis-
covery C18 column (15 cm × 2.1 mm, I.D. 5 μm; Supelco) and eluted with an iso-
cratic ﬂow of acetonitrile:2-propanol (85:15). LC20AB HPLC pumps were used to
deliver solvent at a ﬂow rate of 200 μl min−1. All molecular and fragment ions were
sodiated and hence provide high-resolution values for [M+Na]+. We acquired
full-scan MSn spectra of selected DAG precursor ions by multiple reaction mon-
itoring (MRM), extracted the chromatograms of the high-resolution [M+Na]+
values and used the latter chromatograms for calibration and quantiﬁcation. DAGs
measured included 18:1-20:4 and 18:0-20:4 and the amounts of these species in
cells were quantiﬁed using the standard, 1,2-heptadecanoin (17:0-17:0). DAG levels
were measured by LC-MS-MS using an LC20AB coupled to a hybrid detector IT-
TOF (Shimadzu Corporation, Kyoto, Japan) equipped with an ESI interface. N=
3–5 mice were used for these measurements. DAGs measured included 18:1-20:4,
18:0-20:4, and 16:0-20:4, and the amounts of these species in tissues were quan-
tiﬁed using an external standard, 1,2-heptadecanoin (17:0-17:0, for which a cali-
bration curve had been constructed in pilot experiments for the most abundant
DAG species, 18:0-20:4, and considered valid also for the other DAG species), were
expressed as pmols per mg of wet tissue weight. The calibration curve was also re-
run occasionally, with no observed signiﬁcant changes. All molecular and fragment
ions were sodiated and hence provide high-resolution values for [M+Na]+. As
most 20:4-containing DAG species are present in tissues in trace amounts; in some
cases, we had to overload the column to be sure to detect these molecules. We
acquired full-scan MSn spectra of selected DAG precursor ions by MRM, extracted
the chromatograms of the high-resolution [M+Na]+ values, and used the latter
chromatograms for calibration and quantiﬁcation. The limit of detection (LOD) of
17:0-17:0 was 10 pmol in MS analysis.
Muscle biopsies. All human samples were obtained after the patients had signed
informed consent forms in accordance with the guidelines of the G. Gaslini
Institute Ethics Committee, including experimental protocols for muscle biopsies.
The muscle biopsy was obtained from femoral quadriceps muscle for diagnostic
purposes from patients suspected for DMD. The diagnosis of DMD was also
conﬁrmed by genetic analysis.
Animals care. The experimental protocol was evaluated and approved by the
Institutional Animal Ethics Committee for the use of experimental animals and
conformed to guidelines for the safe use and care of experimental animals in
accordance with the Italian D.L. no. 116 of 27 January 1992 and associated
guidelines in the European Communities Council (86/609/ECC and 2010/63/UE).
For this study, control (C57BL/10ScSnJ) and dystrophic (C57BL/10ScSn-
DMDmdx/J) mice of 5 weeks weighing ~20–25 g were purchased from Charles
River Laboratories (MI, IT). All mice were housed in an individually ventilated cage
system with a 12-h light–dark cycle and received standard mouse chow (Harlan
Teklad) and water ad libitum.
Drug treatment and reagents. Control (C57BL/10ScSnJ) or dystrophic (C57BL/
10ScSn-DMDmdx/J) mice were intraperitoneally (IP) injected with: (a) vehicle
(DMSO); (b) ACEA (2.5 mg Kg−1); or (c) rimonabant (SR141716 0.5 mg Kg−1)
three times per week for 2 weeks. DMSO and ACEA were from Sigma Aldrich.
Rimonabant was from Cayman Chemical Company (USA).
ELISA assays on plasma of control and dystrophic mice. Control and dys-
trophic mice treated with vehicle (DMSO) or rimonabant were previously anes-
thetized with halothane, subsequently the blood was removed by cardiac puncture
and collected into EDTA-treated tubes. Blood cells were then removed by cen-
trifugation for 10 min at 1000–2000×g using a refrigerated centrifuge. The resulting
supernatant or plasma was further ﬁltered in Amicon Ultra-0.5 ml Centrifugal
Filters to concentrate the proteins with a molecular weight >10 kDa. The ELISA
assay was performed by the use of either TNFα (cat. no. KHC3011) or IL-6 (cat. no.
KMC0061) mouse ELISA Kits purchased from Thermo-Fisher scientiﬁc as per the
manufacturer’s instruction.
RNA-seq analysis. Hind limb muscles from normal wild-type C57/BL6 and
C57Bl6 mdxdystrophic mice, used at the speciﬁed age of 8 weeks, were minced and
digested in HBSS (Gibco) containing 2 mgml−1 Collagenase A (Roche), 2.4 Uml−1
Dispase I (Roche), 10 ng ml−1 DNase I (Roche), 0.4 mM CaCl2, and 5 mM MgCl2
for 90 min at 37 °C. Cells were stained with primary antibodies CD31-PB
(eBioscience), CD45-eFluor450 (eBioscience), Ter119-eFluor450 (eBioscience),
F480-PE (eBioscience), CD11b-PC7, Sca-1-FITC (BD Pharmingen and a7integrin-
APC (AbLab)) for 30 min on ice. Cells were ﬁnally washed and resuspended in
HBSS containing 0.2% w/v BSA and 1% v/v penicillin–streptomycin. Flow cyto-
metry analysis and cell sorting were performed on a DAKO-Cytomation MoFlo
High Speed Sorter. Muscle satellite cells (SCs) were isolated as Ter119/CD45/CD31
negative (Lin−), a7-integrin-positive, and Sca-1-negative cells; FAP cells were
isolated as Lin−, a7-integrin-negative, and Sca-1-positive cells. Macrophages
(MPs) were isolated as Lin-positive, F480/CD11b-positive cells. Subsequently, for
RNA-seq analysis, SCs, FAPs, and MPs freshly isolated by FACS from 16 wild-type
C57/BL6 and six C57Bl6 mdx mice, 8-week old, were centrifuged and the pellet was
resuspended in Trizol (Invitrogen) for total RNA extraction. About 100 ng µL−1 of
total RNA was sent in duplicate to IGA for RNA-seq. RNA for the sequencing was
processed using Illumina TruSeq Stranded Total RNA kit Ribo-Zero GOLD on
Illumina Hiseq2500 platform. Mapping of more than 20 millions of reads for each
sample to the mus musculus GRCm38.78 genome was performed using TopHat
2.0.9. Read count was performed with HTSeq-0.6.1p1. Mapped reads were analyzed
with R-studio using DESeq2 to obtain normalized RPKM values and Heat-map
with Z-score function. Sequencing data are available through SRA accession code
SRP143532. For RT-PCR validation, 150 ng of total RNA, isolated with Trizol from
SCs, FAPs, and MPs freshly isolated from wild-type C57/BL6 (n= 4) and three
C57Bl6 mdx (n= 4) mice 8-week old, was retro-transcribed using the Taqman
reverse transcription kit (Applied Biosystems). Real-time quantitative PCR was
performed to analyze relative CB1, Daglα, and Magl gene expression levels using
SYBR Green Master mix (Applied Biosystems) following manufacturer indications.
The values were normalized to the housekeeping gene TBP for SCs and FAPs and
to S16 for MPs.
Rota-rod test. The rotarod test was performed in control and dystrophic mice
immediately before the beginning of the pharmacological treatment (5 weeks) and
at the indicated times following the treatment with vehicle, ACEA, or rimonabant.
Brieﬂy, the rotarod was settled with a start speed of 5 rpm and the mice were placed
on the rotating rod for 30 s. Then, the rotarod was accelerated to 40 rpm in 240 s.
The time (s) when mice dropped from the rod was recorded. The results were
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expressed as an average of two different trials and the interval time of each trial was
30 min.
Weights test. To test the forelimb strength of dystrophic mice treated or not with
ACEA and rimonabant, four weights of 20, 33, 46, and 59 g were used. Mice were
handled by the base of the tail and were allowed to grip the ﬁrst weight (20 g) and a
hold of 3 s was the criterion. If the mouse dropped the weight in less than 3 s, we
tried the same weight again for a maximum of three times. If the mouse held it for
3 s, then we tried it on the next heaviest weight. The mouse was assigned the
maximum time/weight achieved. The ﬁnal total score is calculated as the product of
the number of links in the heaviest chain held for the full 3 s, multiplied by the time
(s) it is held.
Morphological analyses. For morphological analysis, gastrocnemius and quad-
riceps muscle were isolated from wild type, mdx mice injected with vehicle
(DMSO) or rimonabant (SR141716, 0.5 mg Kg−1 IP). After dissection, the muscles
were rapidly embedded in Sakura Tissue-Tek oct (Gentaur) and frozen in
isopentane-cooled liquid nitrogen for cryosection or ﬁxed in PFA and embedded in
parafﬁn. Tissue necrosis was identiﬁed by morphological alterations of myoﬁbers
(i.e., hypercontraction) or loss of sarcolemma integrity and by the presence of
cellular debris in the surrounding interstitial space. Regenerated myoﬁbers were
identiﬁed by the presence of central nuclei, and the diameter or CSA of ﬁbers was
morphometrically analyzed using KS300 image analysis software (Carl Zeiss) or
Image-Quant software (Leica).
Statistical analysis. We tested our datasets for normal distribution and chose an
appropriate test accordingly using GraphPad Prism Version 7.0. Unpaired t-test
was used to test two samples with equal variance. For more than two samples, we
used one-way analysis of variance (ANOVA) followed by Bonferroni post hoc test.
All error bars denote mean values ± SEM as indicated in every ﬁgure legend. The
asterisk denote a P < 0.05 vs. the indicated experimental group.
Data availability
Additional raw data that support the ﬁndings of this study are available from the cor-
responding authors upon reasonable request. RNAseq data are available through SRA
accession code SRP143532.
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